Spike Protein Persistence: What Studies Show
Last updated: October 26, 2026
What published studies report on how long SARS-CoV-2 spike protein and vaccine-encoded spike remain detectable in blood and tissues, how it is measured, and where the evidence is still thin.
Looking for the short answer? How long does spike protein stay in the body? →
Overview
Spike protein persistence describes continued antigen detection after SARS-CoV-2 infection or COVID-19 vaccination. Most individuals clear circulating spike within weeks, but ultra-sensitive assays (Simoa, high-sensitivity ELISA) detect low pg/mL levels in subsets for months to years. The 2026 systematic review synthesizes evidence across bodily fluids and autopsy tissues.
Blood & circulating levels
Positive samples typically fall in the low pg/mL range. Yonker et al. reported ~34 pg/mL of free spike in mRNA vaccine myocarditis cases, sampled within weeks of vaccination. After infection, Swank et al. detected circulating spike mainly in people with Long COVID, up to 12 months after diagnosis. The systematic review cites blood persistence up to ~709 days in outlier cohorts — not representative of the general vaccinated population.
View measured levels & tables →Tissue persistence
Lymph node germinal centers contained vaccine mRNA and spike antigen up to 8 weeks after vaccination in some cases (Röltgen et al., Cell 2022). After infection, an autopsy and imaging study found spike protein accumulated in the skull marrow, meninges and brain of COVID-19 patients, persisting long after the virus had cleared (Rong et al., Cell Host & Microbe 2024). That study did not quantify how long the spike remained and needs independent replication.
Vaccine-derived vs. infection-derived spike
Infection typically produces higher peak antigen loads; vaccine platforms (mRNA, viral vector) show heterogeneous clearance kinetics. Most assays cannot distinguish source without genomic sequencing. Both pathways may contribute to Long COVID/PASC hypotheses in overlapping symptom profiles.
Detection assays
- Simoa — ultra-sensitive; detects sub-pg/mL in research settings
- ELISA — widely used; variable LOD across commercial kits
- IHC / ISH — tissue localization in autopsy/biopsy
- RT-qPCR — vaccine mRNA detection in cells/tissues
Key studies timeline
Long COVID neuropathy: The role of mast cells.
Morcos Zachary L · Journal of neuropathology and experimental neurology
The persistence of COVID-19 vaccine artifacts in bodily fluids and tissues: a systematic review
Various · Future Journal of Pharmaceutical Sciences
SARS-CoV-2 Spike Protein Amyloid Fibrils Impair Fibrin Formation and Fibrinolysis.
Westman Henrik · Biochemistry
Detection of S1 spike protein in CD16+ monocytes up to 245 days in SARS-CoV-2-negative post-COVID-19 vaccine syndrome (PCVS) individuals.
Patterson Bruce K · Human vaccines & immunotherapeutics
Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination.
Fanti Silvia · Circulation
Spike conformational and glycan heterogeneity associated with furin cleavage causes incomplete neutralization of SARS-CoV-2.
Kumar Sahil · Nature communications
Pathogen virulence genes: Advances, challenges and future directions in infectious disease research (Review).
Chen Yun · International journal of molecular medicine
SARS-CoV-2 spike protein-induced inflammation underlies proarrhythmia in COVID-19.
Mezache Louisa · Scientific reports
Mitochondrial Reactive Oxygen Species: A Unifying Mechanism in Long COVID and Spike Protein-Associated Injury: A Narrative Review.
Lee Eunseuk · Biomolecules
Biomarker-Based Risk Assessment Strategy for Long COVID: Leveraging Spike Protein and Proinflammatory Mediators to Inform Broader Postinfection Sequelae.
Yang Ying-Fei · Viruses
Insights into the pathogenic mechanisms associated with the SARS-CoV-2 spike protein.
Argyrou Mia · Journal of structural biology
Post-COVID-19 Vaccination (or Long Vax) Syndrome: Putative Manifestation, Pathophysiology, and Therapeutic Options.
Yong Shin Jie · Reviews in medical virology
Limitations & uncertainty
Heterogeneous cohorts, assay variability, selection bias toward symptomatic patients, and small autopsy series limit generalizability. Persistence does not equal pathogenicity. Causality between spike detection and clinical symptoms remains unproven in randomized studies.